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Abstract  
BACKGROUND: Polycystic ovary syndrome (PCOS) is complex hormonal, metabolic and 
reproductive disorder and is a leading cause of female infertility. Hyperinsulinemia secondary to 
insulin resistance plays important role in the pathogenesis of PCOS.  
AIM: To assess the sensitivity of different indices of insulin resistance and their relevance in a 
clinical setting. 
MATERIAL AND METHODS: A cross-sectional study of 43 patients w ith PCOS and 29 noromo 
ovulatory women as a control group was conducted. Standard clinical, anthropometrical and 
hormonal testing for hyperandrogenism was conducted, as well as oral glucose tolerance test with 
determination of basal and stimulated glucose and insulin values.  
RESULTS: The dynamic I/G index showed the highest sensitivity and specif icity, but the static 
indexes HOMA-IR and QUICKI, although based on only basal glycemic and insulinemic values, 
showed good sensitivity, 90.38% and 94.01% respectively. HOMA-IR show ed signif icant positive 
correlation w ith the stimulated insulin values.  
CONCLUSIONS: Our results support the use of static indexes in the evaluation of insulin 
resistance in women w ith PCOS in a clinical setting, offering a simple assessment of insulin 
resistance in PCOS, w hich holds great prognostic and treatment implications. 
 
 
 
 
Introduction 
 
Polycystic ovary syndrome (PCOS) is 
complex hormonal, metabolic and reproductive 
disorder affecting 10% of females of reproductive age 
and is a leading cause of female infertility [1]. PCOS is 
one of the most frequent endocrinologic dysfunctions 
in women of reproductive age, characterised by the 
association of polycystic ovaries, hyperandrogenism 
and chronic anovulation [2], [3]. Its aetiology remains 
unknown, but it is clear that hyperinsulinemia 
secondary to insulin resistance plays an important role 
in the pathogenesis of reproductive abnormalities [4]. 
PCOS is a diagnosis of exclusion and is defined by 
the Rotterdam classification from 2003 requiring at 
least 2 out of 3 criteria: oligo-ovulation and/or 
anovulation, clinical and/or biochemical 
hyperandrogenism and polycystic ovaries on 
ultrasound [5].  
As early as 1980, Burgen reported that 
women with PCOS have basal and glucose-stimulated 
hyperinsulinemia and noted a significant positive 
linear correlation between the insulin and androgen 
concentrations in women with polycystic ovarian 
syndrome [6]. Insulin resistance and hyperinsulinemia 
is evident  both in lean and obese patients with PCOS 
[7], [8]. The prevalence of insulin resistance in PCOS 
is approximatively 50-60%, compared to 10-20% in 
the general population [9]. It is still controversial 
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whether the hyperinsulinemic state stimulates the 
excessive ovarian production of androgens or if the 
chronic hyperandrogenemic milieu promotes insulin 
resistance. Despite obesity, present in more than half 
of the patients, decreased insulin-stimulated glucose 
utilisation regardless of body mass index has been 
demonstrated in polycystic ovary syndrome [8].  
Several mechanisms have been postulated to 
explain the correlation between the hyperinsulinemia 
and hyperandrogenemia in PCOS. Studies have 
shown a strong negative correlation of basal insulin 
with the levels of sex hormone binding globulin 
(SHBG), suggesting that  the insulin has an inhibitory 
effect on the hepatic production of SHBG, decreasing 
its levels and leading to increased bioactivity of 
testosterone in its free unbound form that emphasises 
the hyperandrogenic characteristics. Insulin resistance 
also predisposes to a visceral type of adiposity, 
reflecting the androgen-like phenotype of PCOS [10], 
[11]. The latest studies revealed unique post-receptor 
defects in the insulin signalling pathways in PCOS. 
Fibroblast cell lines from women with PCOS have 
significantly decreased insulin-stimulated glucose 
incorporation into glycogen, but similar insulin-
stimulated thymidine incorporation, compared to cell 
lines from reproductively normal control women. This 
suggests that there is a selective defect in insulin 
action in PCOS that affects the metabolic, but not the 
mitogenic actions of insulin [4].  
Insulin resistance imposes not only 
disturbances of the glucose metabolism but is also 
associated with a tendency towards atherogenic 
dyslipidaemia and vascular endothelial dysfunction. 
Approximately, 25% to 30% of women with PCOS will 
show impaired glucose tolerance by the age of 30 and 
8% of affected women will develop type 2 diabetes 
annually [12]. Women with PCOS are seen to have 
more extensive coronary artery disease by 
angiography. Hypertension is also observed more 
frequently in these women [13]. Therefore the testing 
for insulin resistance becomes important and integral 
part of the evaluation of patients with PCOS.  
The aim of this study was to assess the 
sensitivity of different indices of insulin resistance and 
their relevance in a cross-sectional study of patients 
with PCOS and noromo ovulatory women as a control 
group.  
 
 
Material and Methods 
 
 A cross-sectional study was conducted at the 
University Clinic of Endocrinology, Diabetes and 
Metabolic Disorders in Skopje, Macedonia, in the 
period between October 2012 and May 2014. In this 
study, 43 patients were enrolled with hyperinsulinemic 
PCOS and a control group of 29 noromo ovulatory 
women with regular menstrual cycles, without clinical 
or biochemical signs of hyperandrogenism and no 
prior known endocrinologic diseases. PCOS was 
diagnosed according to the criteria from The 
Rotterdam ESHRE/ASRM-Sponsored PCOS 
Consensus Workshop Group [5]. Patients presenting 
with thyroid disorders or neoplastic causes of 
hyperandrogenemia such as androgen-secreting 
tumours, congenital adrenal hyperplasia and 
Cushing's syndrome were excluded from the study.  
 Patients with PCOS were grouped according to 
body mass index (BMI) into PCOS with normal BMI ≤ 
25 kg/m^2 (PCOS N) and PCOS with high BMI > 25 
kg/m^2 (PCOS H).  
Hormonal parameters were assessed in the 
follicular phase of the menstrual cycle or at any given 
day in women with absent menstrual cycle in the 
previous two or more months. Blood samples for 
hormonal and biochemical analyses were obtained by 
venipuncture between 08:00 and 10:00 h, after an 
overnight fast of 12 hours. Anthropometrical 
measurements and clinical assessment of signs of 
hyperandrogenism were conducted at the visit. 
Transvaginal ult rasound scan of the ovaries was 
performed at the University clinic of Gynaecology 
using a 6,5 MHz transducer in order to determine the 
total number of early antral follicles. All patients 
underwent an oral 75g glucose tolerance test (OGTT) 
after an overnight fast of at least 12 hours during 
which basal values of glucose and insulin were 
measured at baseline, as well as post-load glucose 
and insulin values at 60 and 120 minutes.  
Serum estradiol (E2), luteinizing hormone 
(LH), follicle stimulating hormone (FSH), testosterone 
(T), androstenedione (A), dehidroepiandrostenedione-
sulphate (DHEA-s) and prolactin (PRL) levels were 
measured by electrochemiluminescence 
immunoassay on a Roche Elecsys 1010/2010 
automated immunoassay analyser. Sex hormone 
binding globulin (SHBG) measurements were 
performed by enzyme-linked immunosorbent assay on 
an IMX Abbott semiautomatic analyser (values of 
these tests are not shown in results section). Insulin 
was measured in serum with microparticle enzymatic 
assay (MEA) on the semiautomatic analyser IMX 
Abbot. Glucose was determined in plasma with 
glucose-oxidase method on the glycemic analyser 
Beckmann. Free androgen index (FAI) was calculated 
using the standard formula: testosterone/SHBG × 100  
(values of these tests are not shown in results 
section).  
Established direct methods for measuring 
insulin sensitivity in vivo are relatively complex. 
Therefore, simple surrogate indexes for insulin 
sensitivity/resistance which is derived from blood 
insulin and glucose concentrations under fasting 
conditions (steady state) or in the postprandial state 
(dynamic) was calculated. Based on the results of 
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basal and post-load glucose and insulin levels 
obtained during OGTT, several indexes of insulin 
resistance were calculated for all of the patients. 
Homoeostasis model of insulin resistance (HOMA -IR) 
was calculated using the formula: (fasting insulin 
(µU/ml) x basal glucose (mmol/l))/22.5. 
The quantitative insulin sensitivity check 
index (QUICKI) was derived using the inverse of the 
sum of the logarithms of the fasting insulin and 
fasting glucose, using the formula: 1/(log(fasting 
insulin µU/mL) + log(fasting glucose mmol/l)). The 
sum of insulin measured at 0, 60 and 120 minutes 
divided by the sum of glucose at 0, 60 and 120 
minutes was calculated as a dynamic index I/G [14]. 
All statistical procedures were run using the 
StatSoft Statistica 7 software. Statistical significance 
was set at p < 0.05. Normality of distribution was 
evaluated with the one-sample Kolmogorov-Smirnoff 
test. Comparisons of means were performed with one-
way ANOVA and general linear model multi-variance. 
Correlations were evaluated with the calculation of the 
Spearman coefficient.  
 
 
Results 
 
In this study, 43 patients were diagnosed as 
having PCOS according to the Rotterdam diagnostic 
criteria and had basal or stimulated hyperinsulinemia 
during OGTT while the control group consisted of 29 
women with normal glucose and insulin values during 
OGTT and normal hormonal status. The basic clinical 
data for the patient groups (PCOS N, PCOS H and 
control group) as well the results for insulinemia and 
glycaemia during the OGTT are shown in Table 1.  
Table 1: Basal clinical, anthropometrical, hormonal and 
metabolic values in the three groups 
  
 
Control group 
PCOS N  
BMI ≤ 25 
kg/m^2 
PCOS H  
BMI >25 kg/m^2 
 n 29 12 31 
Age (years) 22.36 ± 3.82 21.42 ± 3.94 24.97 ± 6.29 
BMI (kg/m
2
)  23.16 ± 3.24 23.75 ± 1.22 33.13 ± 5.56*  
Menstrual cycl e length (days)  49 ± 2.6 77.92 ± 64.39 67.76 ± 45.29 
Testosterone (ng/ml)  1.32 ± 0.77 1.5 ± 1.4 1.72 ± 0.95 
Fasting insulin (µU/ml)  10.45 ± 2.63 24.15 ± 35.57 22.89 ± 7.77 
Stimul ated insulin at 60 min (µU/ml) 44.95 ± 20.11 148.74 ± 80.87 166.95 ± 96.68 
Stimul ated insulin at 120 min (µU/ml) 28.85 ± 9.17 102.65 ± 78.6 148.96 ± 102.66 
Fasting glucose ( mmol/L)  4.43 ± 0.58 4.75 ± 0.7 4.84 ± 0.63 
Stimul ated glucose at 60 min (mmol/L)  5.65 ± 1.04 6.96 ± 1.66 8.26 ± 2.32 
Stimul ated glucose at 120 min ( mmol/L)  4.85 ± 072 5.75 ± 1.05 6.63 ± 2.06 
*, p < 0.001.  
 
Most of the patients were in the 21 to 30 
years age group, with an average age of the patients 
in the PCOS H group higher (24.97 ± 6.29 years) in 
comparison to the PCOS N group, but not statistically 
significant. A statistically significant difference 
(p<0.001) was found in the BMI of patients with PCOS 
H in comparison to the control group. There was no 
statistically significant difference in the glycemic status 
between the groups, but still, the PCOS H group had 
higher average basal glycaemia values and more 
markedly higher glycemic excursions post load (Fig. 
1).  
 
Figure 1: Basal and post load glycemic values in the groups 
 
The PCOS group showed both basal and 
post-load hyperinsulinemia. The stimulated insulin 
values were significantly higher both in PCOS N and 
PCOS H groups compared to the controls, 
independent of obesity status, which was used as 
criteria for group division (Fig. 2).  
 
 
Figure 2: Basal and stimulated insulin values in the groups 
 
There was no statistically significant 
difference between the values of fasting glycaemia 
between the groups, although higher post load 
glycemic excursions were noted in PCOS patients, 
especially at 60 minutes during OGTT. There was no 
significant difference in the degree of stimulated 
hyperinsulinemia in lean and obese patients with 
PCOS (Table 2).  
Table 2: Statistical difference in the basal and stimulated 
glucemic and insulinemic values between lean and obese 
PCOS patients 
 
Mean 
PCOS N  
Mean 
PCOS H  
St.D. 
PCOS N  
St.D. 
PCOS H  
t-val ue p 
Age 21.42 24.97 3.94 6.29 -1.81 0.076 
BMI 23.75 33.13 1.21 5.56 -5.75 <0.001* 
MNZ 77.92 67.76 64.38 45.30 0.57 0.568 
Testosterone 1.50 1.72 1.40 0.95 -0.56 0.579 
Basal insulin 24.15 22.90 35.57 7.77 0.19 0.851 
Stimul ated insulin at 60' 148.74 166.95 80.87 96.69 -0.58 0.566 
Stimul ated insulin at 120'  102.65 148.96 78.61 102.66 -1.41 0.166 
Basal glucose 4.74 4.84 0.70 0.63 -0.42 0.674 
Stimul ated glucose at 60' 6.94 8.26 1.67 2.32 -1.74 0.090 
Stimul ated glucose at 120'  5.75 6.63 1.06 2.06 -1.34 0.189 
*, p < 0.001.  
 
For the PCOS groups, three indexes of insulin 
resistance were calculated: homoeostasis model of 
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insulin resistance (HOMA-IR) and the quantitative 
insulin sensitivity check index (QUICKI) as static 
indexes and the sum of insulinemia versus the sum of 
glycaemia (I/G) as a dynamic index. All of the values 
were compared to the values obtained in the control 
group and sensitivity and specificity were calculated 
for each index. The results for sensitivity and 
specificity of insulin indexes in the entire PCOS group 
are given in Table 3.  
Table 3: Sensitivity and specificity of indexes of insulin 
resistance 
 
I/G HOMA-IR QUICKI 
Control group 5.65 ± 1.47 2.06 ± 0.65 0.61 ± 0.04 
PCOS N  15.78 ± 11.13 5.02 ± 7.2 0.59 ± 0.14 
PCOS H  17.17 ± 9.6 4.92 ± 1.75 0.49 ± 0.03 
PCOS all  17.42 ± 9.91 4.2 ± 3.84 0.51 ± 0.07 
Sensiti vity % 96.02 90.38 94.01 
Specificity % 92.64 84.09 86.21 
 
The I/G index showed the highest sensitivity 
and specificity, being derived from both basal and 
post load values of glycaemia and insulinemia. 
Although the static indexes HOMA-IR (90.38%) and 
QUICKI (94.01%) are based on only basal glycemic 
and insulinemic values, they showed good sensitivity. 
HOMA-IR values also showed significant positive 
correlation with the insulin values at 60 minutes (r = 
0.42; p < 0.005) and at 120 minutes post load (r = 
0.52; p < 0.0003) during OGTT (Fig. 3). 
 
Figure 3: Correlation of HOMA-IR with post-load insulinemic values 
at 60 and 120 minutes 
 
 
Discussion 
 
The polycystic ovary syndrome is not only the 
most common underlying cause of anovulation in 
women in the reproductive period but is also 
associated with characteristic dysfunctions of the 
insulin action that have an important impact on the 
possible metabolic disturbances appearing later in life 
in women with PCOS. The association between the 
impaired carbohydrate metabolism and 
hyperandrogenism was first described in 1921 by 
Archard and Thiers as “diabetes in a bearded female”  
[15]. Kierland in 1947 described the characteristic skin 
lesion, acanthosis nigricans, which can be seen in 
women with hyperandrogenism and in patients with 
diabetes, as an epiphenomenon of the insulin 
resistance [16]. Dunaif et al investigated the 
characteristics of hyperandrogenic women with 
acanthosis nigricans; they found impaired glucose 
tolerance in 20% of the patients [17]. According to the 
revised criteria of the world health organisation 
(WHO), later studies determined the prevalence of 
impaired glucose tolerance of 20-40% in women with 
PCOS, compared to 5.3% prevalence of impaired 
glucose tolerance in the control population [18]. This 
high incidence led towards more extensive research 
of the role of insulin resistance in PCOS. 
  Insulin resistance is seen in 50-60% of 
women with PCOS, while almost 10% of them have a 
certain degree of glucose intolerance or diabetes at 
the time of diagnosing the syndrome [9], [19]. Pesant 
et al, reported that during three years follow-up period, 
up to 25% of women with PCOS, initially with normal 
glucose metabolism, will develop some degree of 
glucose metabolism abnormalities [20]. In our study, 
we have demonstrated that the fasting glycaemia is 
not a marker of metabolic dysregulation, since there 
was no statistically significant difference between the 
values of fasting glycaemia between the groups, 
although higher post load glycemic excursions were 
noted in PCOS patients, especially at 60 minutes 
during OGTT. Our data confirm that insulin resistance 
is not exclusively seen in obese patients with PCOS, 
but marked post load hyperinsulinemia was also noted 
in lean patients with PCOS. There was no significant 
difference in the degree of stimulated 
hyperinsulinemia in lean and obese patients with 
PCOS, confirming the fact that insulin resistance in 
PCOS is independent of obesity, which was taken as 
a group dividing factor.  
Insulin resistance is characterised by an 
inability of normal amounts of insulin to achieve the 
normal predicted response, often in the clinical setting 
of central adiposity. To achieve euglycemia, the 
pancreas over secretes insulin [21]. Investigators 
define insulin resistance based on hyperinsulinemic-
euglycemic clamp techniques. Hyperinsulinemic-
euglycemic clamp techniques rely on an intravenous 
insulin infusion to maintain steady serum glucose 
concentrations at fasting levels to measure glucose 
uptake. Lower glucose uptake signifies resistance to 
insulin action (insulin resistance). Since the technique 
requires intravenous infusions, frequent blood 
sampling,  extensive time and significant  financial 
resources, it is experimentally useful but rarely 
applicable in a clinical setting [22]. Therefore, many 
derived indexes for assessment of insulin resistance 
have been proposed. Clamp techniques have been 
used as comparisons to validate other modes of 
assessment of insulin resistance.  
The homeostatic model assessment of insulin 
resistance (HOMA-IR) has been compared to clamp 
techniques with good results [22]. One major limitation 
of HOMA rests on the fact that many adolescents with 
PCOS display stimulated but not fasting metabolic 
abnormalities. In fact, HOMA in young PCOS patients 
missed 50% of insulin resistance as compared to 
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OGTT with insulin-AUC calculations [23]. I/G ratio 
correlated strongly with clamp-demonstrated insulin 
resistance in a small study of PCOS women, showing 
evidence of insulin resistance in both lean and obese 
women with PCOS [24]. Quantitative insulin sensitivity 
check index (QUICKI) was developed to improve the 
sensitivity of fasting measurements. QUICKI has been 
shown to correlate well to clamp measurements in 
obese and non-obese patients [25]. QUICKI also 
demonstrates correlation with HOMA-IR. In our study, 
the I/G ratio showed the highest sensitivity, which was 
expected because the index calculations are based on 
both basal and simulated values of insulin and 
glucose, but the static indexes showed also very high 
sensitivity. The sensitivity and specificity of HOMA-IR 
were comparable to the QUICKI index, bearing in 
mind the fact that our studied population did not 
include adolescents. The correlation of HOMA-IR with 
the stimulated insulin values indicates that this index 
gives a relevant value of the level of insulin resistance 
in women with PCOS.  
Our results are in accordance with several 
studies that support the use of static indexes of insulin 
resistance in the evaluation of insulin resistance in 
women with PCOS in a clinical setting. Furthermore, 
the method is simple, quick and easy to execute in 
contrast to the complicated and expensi ve 
hyperinsulinemic-euglycemic clamp. The diagnosis of 
insulin resistance holds great prognostic and 
treatment implications. All women with PCOS should 
be screened for the presence of insulin resistance as 
well as assessed for other stigmata of the insulin  
resistance syndrome such as hypertension, 
dyslipidemia, central obesity, and glucose intolerance.  
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